Llwytho...
Ginsenoside Rg3 promotes the antitumor activity of gefitinib in lung cancer cell lines
Lung cancer is one of the most common types of cancer with one of the highest incidence and mortality rates. Gefitinib is widely used for the treatment of non-small cell lung cancer (NSCLC). However, issues regarding drug resistance, toxicity and limited applicability have been associated with gefit...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Exp Ther Med |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
D.A. Spandidos
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6307378/ https://ncbi.nlm.nih.gov/pubmed/30651886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2018.7001 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|